Recap - First, W.V. Democratic Senator Joe Manchin introduced a bill last week to overturn the FDA’s marketing approval of Zohydro ER, an opioid pain product developed by Zogenix Inc. (ZGNX) and approved just last … Continue Reading
Read nowInsights - Sarepta Therapeutics (SRPT) last Thursday morning released its fourth quarter and full-year 2013 financial results and hosted a conference call for investors. SRPT’s 2014 outlook … Continue Reading
Read nowRecap - Shares of Tekmira Pharmaceuticals (TKMR) have been on an absolute tear. Already since our January 7th reiteration to PropThink Premium members to own the stock, TKMR is up a … Continue Reading
Read nowInsights - Arrowhead Research (ARWR), which develops targeted RNAi therapeutics, pulled down gross proceeds of $104 million on Wednesday through the sale of its common stock, a … Continue Reading
Read nowResearch - Update from Friday, January 31st at 9:45 AM ET Today the company revealed that it’s selling 5.76M shares at $21. What would have originally been … Continue Reading
PremiumRecap - The congrats this week went to PropThink contributor Ivan Deryugin for his early December suggestion to buy BDSI ahead of a crucial phase 3 readout. The position … Continue Reading
Read nowResearch - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
Premium
